
BAYZF
Healthcare · Drug Manufacturers - General · $61.38B market cap
$62.48+0.28 (+0.5%)Nov 13, 9:30 AM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 13, 2025 | Before the open | — | 1.39 | — |
| Mar 5, 2025 | Before the open | — | -0.36 | — |
| Nov 12, 2024 | Before the open | — | -4.68 | — |
| Aug 6, 2024 | Before the open | — | -0.04 | — |
| May 14, 2024 | Before the open | — | 2.21 | — |
| Mar 5, 2024 | Before the open | — | 1.46 | — |
| Sep 30, 2021 | Time not confirmed | — | 0.10 | — |
| Jun 30, 2021 | Time not confirmed | — | -2.82 | — |
| Mar 31, 2021 | Time not confirmed | — | 2.49 | — |
| Dec 31, 2020 | Time not confirmed | — | 0.48 | — |
| Aug 3, 2020 | After the close | 0.44 | 0.44 | 0.0% |
| Apr 26, 2020 | After the close | 2.64 | 2.67 | +1.1% |
| Feb 26, 2020 | After the close | 1.25 | 1.29 | +3.2% |
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics…
| After the close |
| 1.17 |
| 1.16 |
| -0.9% |
| Aug 6, 2019 | Before the open | 0.46 | 0.46 | 0.0% |
| Apr 24, 2019 | After the close | 2.66 | 2.55 | -4.1% |
| Feb 26, 2019 | After the close | 2.11 | 1.10 | -47.9% |
| Nov 12, 2018 | After the close | 0.97 | 1.19 | +22.7% |
| Sep 4, 2018 | After the close | 1.44 | 1.54 | +6.9% |
| May 2, 2018 | After the close | 2.03 | 2.24 | +10.3% |
| Feb 27, 2018 | After the close | 1.15 | 1.39 | +20.9% |